Predicted protein targets (top 2)
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL2301815 | 0.92 | PIK3CG (0.61) | PIK3CGPIK3CD | |
| SCHEMBL2303766 | 0.86 | PIK3CG (0.73) | PIK3CGPIK3CD | |
| SCHEMBL2300290 | 0.84 | PIK3CG (0.62) | PIK3CGPIK3CD | |
| SCHEMBL2300757 | 0.80 | PIK3CG (0.72) | PIK3CGPIK3CD | |
| SCHEMBL188285 | 0.79 | PIK3CD (0.81) | PIK3CGPIK3CD | |
| SCHEMBL9998336 | 0.79 | PIK3CG (0.53) | PIK3CGPIK3CD | |
| SCHEMBL2300343 | 0.78 | PIK3CD (0.62) | PIK3CGPIK3CD | |
| SCHEMBL2303925 | 0.78 | PIK3CD (0.69) | PIK3CGPIK3CD | |
| SCHEMBL189431 | 0.77 | PIK3CD (0.77) | PIK3CGPIK3CD | |
| SCHEMBL2301020 | 0.76 | PIK3CD (0.72) | PIK3CGPIK3CD |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 25 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20110319410-A1 | PYRAZINE DERIVATIVES AND USE AS PI3K INHIBITORS | MERCK SERONO SA (CH) | 2011-12-29 | — | — | US | claimed |
| US-8071597-B2 | Pyrazine compounds and uses as PI3K inhibitors | MERCK SERONO SA (CH) | 2011-12-06 | — | — | US | claimed |
| US-20090082356-A1 | Pyrazine Derivatives and Use as P13k Inhibitors | MERCK SERONO SA (CH) | 2009-03-26 | — | — | US | claimed |
| JP-2009506015-A | — | — | 2009-02-12 | — | — | JP | claimed |
| EP-1917252-A1 | PYRAZINE DERIVATIVES AND USE AS PI3K INHIBITORS | LABORATOIRES SERONO S.A. (CH) | 2008-05-07 | — | — | EP | claimed |
| WO-2007023186-A1 | PYRAZINE DERIVATIVES AND USE AS PI3K INHIBITORS | LABORATOIRES SERONO S.A. (CH) | 2007-03-01 | — | — | WO | claimed |
| US-8877757-B2 | Pyrazine derivatives and use as PI3K inhibitors | MERCK SERONO SA (CH) | 2014-11-04 | — | — | US | disclosed |
| US-8877757-B2 | Pyrazine derivatives and use as PI3K inhibitors | MERCK SERONO SA (CH) | 2014-11-04 | — | — | US | disclosed |
| US-8877757-B2 | Pyrazine derivatives and use as PI3K inhibitors | MERCK SERONO SA (CH) | 2014-11-04 | — | — | US | disclosed |
| US-20110319410-A1 | PYRAZINE DERIVATIVES AND USE AS PI3K INHIBITORS | MERCK SERONO SA (CH) | 2011-12-29 | — | — | US | disclosed |
| US-20110319410-A1 | PYRAZINE DERIVATIVES AND USE AS PI3K INHIBITORS | MERCK SERONO SA (CH) | 2011-12-29 | — | — | US | disclosed |
| US-20110319410-A1 | PYRAZINE DERIVATIVES AND USE AS PI3K INHIBITORS | MERCK SERONO SA (CH) | 2011-12-29 | — | — | US | disclosed |
| US-20110312960-A1 | PYRAZINE DERIVATIVES AND USE AS PI3K INHIBITORS | MERCK SERONO SA (CH) | 2011-12-22 | — | — | US | disclosed |
| EP-2365810-A2 | PHOSPHATIDYLINOSITOL-3-KINASE P110 DELTA-TARGETED DRUGS IN THE TREATMENT OF CNS DISORDERS | The U.S.A. As Represented By The Secretary, Department Of Health And Human Services (US) | 2011-09-21 | — | — | EP | disclosed |
| EP-2351745-A1 | Pyrazine derivatives and use as PI3K inhibitors | Merck Serono S.A. (CH) | 2011-08-03 | — | — | EP | disclosed |
| WO-2010065923-A2 | PHOSPHATIDYLINOSITOL-3-KINASE P110 DELTA-TARGETED DRUGS IN THE TREATMENT OF CNS DISORDERS | THE UNITED STATES OF AMERICA, AS REPRESENTED BY THE SECRETARY, DEPARTMENT OF HEALTH AND HUMAN SERVICES (US) | 2010-06-10 | — | — | WO | disclosed |
| US-20090082356-A1 | Pyrazine Derivatives and Use as P13k Inhibitors | MERCK SERONO SA (CH) | 2009-03-26 | — | — | US | disclosed |
| US-20090082356-A1 | Pyrazine Derivatives and Use as P13k Inhibitors | MERCK SERONO SA (CH) | 2009-03-26 | — | — | US | disclosed |
| US-20090082356-A1 | Pyrazine Derivatives and Use as P13k Inhibitors | MERCK SERONO SA (CH) | 2009-03-26 | — | — | US | disclosed |
| WO-2007023186-A1 | PYRAZINE DERIVATIVES AND USE AS PI3K INHIBITORS | LABORATOIRES SERONO S.A. (CH) | 2007-03-01 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20090082356-A1 | Pyrazine Derivatives and Use as P13k Inhibitors | PI4KA, PIP5K1B, PDPK1 | PIK3CG 110/4885PIK3CD 74/4885 |
| US-20110312960-A1 | PYRAZINE DERIVATIVES AND USE AS PI3K INHIBITORS | PIK3R5, PIK3CD, PIK3CA | PIK3CG 4/4885PIK3CD 2/4885 |
| US-20110319410-A1 | PYRAZINE DERIVATIVES AND USE AS PI3K INHIBITORS | PIK3R5, PIK3CD, PIK3CA | PIK3CG 4/4885PIK3CD 2/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.